TGTX 12.24 Tg Therapeutics $TGTX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 3:21 PM

TGTX 12.24 Tg Therapeutics $TGTX Hit a 52 week high of 12.50 Currently at 12.24 -0.31 -2.47% With a day low of 12.10 and a total volume of 50,855.

TGTX Tg Therapeutics Recent Headline News

TG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - 18 mins ago

TGTX: 12.97 (+0.42)

TG Therapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:10AM CST

TGTX: 12.97 (+0.42)

TG Therapeutics posts 3Q loss
Automated Insights - Tue Nov 11, 4:11AM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Tuesday reported a loss of $17.5 million, or 51 cents per share, in its third quarter.
TGTX: 12.97 (+0.42)

Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.07 (-0.06), PCMI: 8.93 (+0.13), ACHN: 12.52 (-0.33), TGTX: 12.97 (+0.42), AGIO: 82.33 (+0.55), LIOX: 5.40 (-0.14), PLNR: 6.61 (-1.07)

TG Therapeutics misses by $0.19
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:12PM CST

TGTX: 12.97 (+0.42)

TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Mon Nov 10, 3:20PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.
TGTX: 12.97 (+0.42)

TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST

TGTX: 12.97 (+0.42)

TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 12.97 (+0.42)

TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 12.97 (+0.42)

Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 12.97 (+0.42)

Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 59.26 (+0.45), TGTX: 12.97 (+0.42), LGND: 56.96 (+1.28), AMGN: 162.13 (-0.96)

TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 12.97 (+0.42)

Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 12.97 (+0.42)

TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"

. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option.
TGTX: 12.97 (+0.42)

TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 81.15 (+9.34), ABAX: 53.71 (+0.77), TGTX: 12.97 (+0.42), EGRX: 13.31 (-0.19)

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 12.97 (+0.42)

UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 12.97 (+0.42)

TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:12AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16 Annual Rodman & Renshaw Global Investment Conference being held at the New York Palace Hotel. Mr. Weiss' presentation is scheduled to take place on Tuesday, September 9, 2014 at 1:40 PM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section of the Company's website at www.tgtherapeutics.com.
TGTX: 12.97 (+0.42)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Darden Faces Class Action Over Reimbursement Failures

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...